SCHEDULE: Vanguard Discloses 6.35% Stake in Coeptis Therapeutics

The Vanguard Group and its affiliates reported a 6.35% beneficial ownership stake in Coeptis Therapeutics Holdings Inc. as of December 31, 2025.

Summary

• The Vanguard Group and its affiliates beneficially own 339,486 shares of Coeptis Therapeutics Holdings Inc. common stock.
• This ownership represents 6.35% of the company's outstanding common stock.
• The beneficial ownership was reported as of December 31, 2025.
• Vanguard Total Stock Market Index Fund Investor Shares, a subsidiary, reported beneficial ownership of 268,093 shares, representing 5.02% of the class, with sole voting power over these shares.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• An internal realignment occurred at The Vanguard Group, Inc. on January 12, 2026, where it ceased performing portfolio management services or administering proxy voting, with subsidiaries expected to report beneficial ownership separately.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a substantial stake by a major institutional investor like Vanguard can lend credibility and stability to the shareholder base, although it's primarily a passive investment.

Positives

• A major institutional investor, The Vanguard Group, holds a significant 6.35% stake in Coeptis Therapeutics Holdings Inc., indicating institutional confidence.
• The investment is for ordinary course of business, not for control, suggesting a passive, long-term investment strategy.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional ownership by major index fund managers like Vanguard is common for publicly traded companies, especially those included in broad market indices. This filing reflects a standard passive investment by Vanguard, rather than a strategic move specific to Coeptis Therapeutics' industry position.

Stakeholder Impact

• Shareholders: Increased institutional ownership can enhance liquidity and potentially reduce volatility. It signals that a large, reputable investor holds a stake.
• Company Management: The presence of a significant institutional investor may encourage adherence to best practices in corporate governance, although Vanguard's stake is passive.

Next Steps

• The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

The filing indicates a significant, passive institutional stake by Vanguard. While this provides a baseline level of institutional confidence, it does not offer new operational or financial insights into Coeptis Therapeutics Holdings Inc. that would warrant a 'buy' or 'sell' recommendation. It primarily confirms a stable institutional presence.

Keywords

Coeptis Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake, 19207A207